TScan Therapeutics (TCRX)
NASDAQ:TCRX
US Market
Holding TCRX?
Track your performance easily

TScan Therapeutics (TCRX) Financial Statements

175 Followers

TScan Therapeutics Financial Overview

TScan Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.249; its P/E ratio is -4.42; TScan Therapeutics is scheduled to report earnings on November 6, 2024, and the estimated EPS forecast is $-0.32. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue$ 536.00K$ 566.00K$ 7.21M$ 3.89M$ 3.15M
Gross Profit$ 536.00K$ 566.00K$ 7.21M$ 3.89M$ 3.15M
EBIT$ -30.71M$ -29.18M$ -18.76M$ -22.02M$ -23.08M
EBITDA$ -29.59M$ -27.93M$ -17.48M--
Net Income Common Stockholders$ -31.66M$ -30.14M$ -19.61M$ -23.00M$ -24.05M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 297.68M$ 162.78M$ 192.04M$ 215.42M$ 208.84M
Total Assets$ 374.87M$ 240.83M$ 272.15M$ 291.38M$ 316.92M
Total Debt$ 91.07M$ 91.76M$ 92.43M$ 86.98M$ 87.74M
Net Debt$ -206.60M$ -71.02M$ -99.61M$ -128.44M$ -121.10M
Total Liabilities$ 119.65M$ 117.86M$ 121.28M$ 122.42M$ 126.32M
Stockholders Equity$ 255.22M$ 122.97M$ 150.87M$ 168.96M$ 190.61M
Cash Flow-
Free Cash Flow$ -27.09M$ -29.97M$ -24.23M--
Operating Cash Flow$ -26.23M$ -29.27M$ -23.77M$ 8.02M-
Investing Cash Flow$ -33.72M$ 36.16M$ 1.91M$ -61.41M-
Financing Cash Flow$ 161.59M$ 258.00K$ 19.00K$ -252.00K-
Currency in USD

TScan Therapeutics Earnings and Revenue History

TScan Therapeutics Debt to Assets

TScan Therapeutics Cash Flow

TScan Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis